… of advanced ovarian cancer with PARP inhibitors is now an established … outcomes can be expected with PARP inhibitors, as was discussed … led to the use of PARP inhibitor maintenance in advanced … What are your takeaways of PARP inhibitor maintenance for the HRD …

… , Proteasome Inhibitors, Histone Deacetylase Inhibitors, PARP Inhibitors, CDK Inhibitors, BCL-2 … Histone Deacetylase Inhibitors 4) By PARP Inhibitors: Olaparib, Niraparib, Rucaparib, Talazoparib …

… as poly (ADP-ribose) polymerase (PARP) inhibitors and immunotherapies. How Is …

… for olaparib compared with other PARP inhibitors, and we know that … associated with the use of PARP inhibitors. OncLive: What were the … than half by going on [PARP inhibitor] maintenance therapy. What questions …

… cancer drug known as a PARP inhibitor1, to the standard treatment …

… developed in combination with the PARP inhibitor, olaparib, in patients with … monotherapy and in combination with PARP inhibition and other DNA-damaging … settings of BRCA variants and PARP inhibitor resistance, to enhance target …

… subset of uterine leiomyosarcomas, as PARP inhibition with olaparib amplifies the …

… , leading to caspase-3 and PARP cleavage. This suppresses tumor cell …

… collectively established the role of PARP inhibition in extending progression-free … rationale for early incorporation of PARP inhibition into treatment paradigms and …

… (PROC) previously exposed to a PARP inhibitor LBA38: Phase 3 study … were previously treated with a PARP inhibitor before enrolling on the …